3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
108
Endometrial Neoplasms
16
Polycystic Ovary Syndrome
9
Neoplasm Metastasis
9
Ovarian Neoplasms
7
Neoplasms
7
Advanced Breast Cancer
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Fallopian Tube Neoplasms
4
Recurrence
3
Infertility
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Squamous Cell Carcinoma of Head and Neck
2
Progesterone Resistance
2
Neoplasms by Site
2
Hereditary Sensory and Autonomic Neuropathies
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Endometrial Hyperplasia
2
Cystadenocarcinoma, Serous
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Breast Cancer Metastatic
2
Breast Cancer Female
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Interventions
Carboplatin
6
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Letrozole
×
1 year
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled